Your session is about to expire
← Back to Search
Ceralasertib + Durvalumab for Lung Cancer (LATIFY Trial)
LATIFY Trial Summary
This trialwill test a new drug combo to treat advanced lung cancer after other treatments have failed.
LATIFY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLATIFY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LATIFY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung cancer is a mix of small cell and non-small cell types.I had cancer before, but it was treated over 5 years ago and hasn't come back.Women who can have babies need to have a negative pregnancy blood test.I have had more than one platinum-based chemotherapy for my cancer.I stopped my previous anti-PD(L)1 therapy due to severe side effects.My cancer has worsened despite my most recent treatment.I have been treated with more than one anti-PD-(L)1 therapy.I have not had severe immune side effects from previous anti-PD(L)1 therapy.I have previously been treated with an ATR inhibitor.I have lasting side effects from cancer treatment that are moderate to severe.My lung cancer is advanced or has spread, as confirmed by tests.I've had treatments for advanced lung cancer including anti-PD-(L)1 and platinum-based therapy.My organs and bone marrow are working well.I haven't needed extra immunosuppressants beyond corticosteroids for side effects, and I'm not on more than 10 mg of prednisone daily.I weigh more than 30 kg and do not have severe weight loss due to cancer.My cancer is not caused by changes in the EGFR or ALK genes.I have or had an autoimmune or inflammatory disorder.All side effects from my previous immunotherapy have gone away.You are expected to live for at least 12 more weeks.I am fully active or can carry out light work.
- Group 1: Group A: Ceralasertib plus durvalumab combination therapy
- Group 2: Group B: Docetaxel monotherapy
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How can people with this condition sign up for the trial?
"The study, which was first shared on September 15th, is looking for volunteers. The information available on clinicaltrials.gov was last updated on October 7th, 20202."
How many people can volunteer for this clinical trial at most?
"Accessing the information available on clinicaltrials.gov, it appears as though this study is still recruiting patients. This trial was first made public on September 15th, 2020 and the most recent update was October 7th, 2020. The aim is to enroll 580 individuals across 11 different research sites."
Could you tell me how many research centers are participating in this project?
"To limit travel-related complications, it is best to select a trial site near you from the 11 available locations. These include clinics in Atlanta, Allentown and Los Angeles among other cities."
What are ceralasertib and durvalumab's side effects?
"Group A: Ceralasertib plus durvalumab combination therapy is considered safe, with a score of 3. This is due to the fact that it is a Phase 3 trial, which implies that in addition to some efficacy data, there are also multiple rounds of safety data supporting this conclusion."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger